[ET Net News Agency, 4 August 2025] UBS raised the target price for Akeso (09926) to  
HKD197.5 from HKD112.1 and maintained the "buy" rating. 
  The research house said Akeso has made good progress on R&D and commercialisation for 
ivonescimab (AK112, PD-1/VEGF). (rc)



 
 